- Home
- About Us
- Industry
- Innovation
- Market
- Products
-
Responsibility
Responsibility
-
Contact
Contact
Categroies
1/1
Number of views:
1000
Regorafenib
2. Patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have previously received imatinib mesylate and sunitinib malate.
3. Hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment.
Retail price
0.0
元
Market price
0.0
元
Number of views:
1000
Product serial number
Category
Antitumor
Quantity
-
+
Stock:
0
1
Details
Cas No.:
835621-07-3
Indication:
1. It is suitable for the treatment of metastatic colorectal cancer who have previously received chemotherapy based on fluorouracil, oxaliplatin and irinotecan, and who have previously received or are not suitable for anti-VEGF therapy and anti-EGFR therapy (RAS wild type) (mCRC) patients.
2. Patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have previously received imatinib mesylate and sunitinib malate.
3. Hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment.
1. It is suitable for the treatment of metastatic colorectal cancer who have previously received chemotherapy based on fluorouracil, oxaliplatin and irinotecan, and who have previously received or are not suitable for anti-VEGF therapy and anti-EGFR therapy (RAS wild type) (mCRC) patients.
2. Patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have previously received imatinib mesylate and sunitinib malate.
3. Hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment.
Previous
Dabrafenib
Next
None
keyword：Chemical products，Chinese medicine products
Related products
Inquiry
Mobile
+8613637076726 
Contact 